UnitedHealth (NYSE: UNH) UHC CEO receives 102 dividend-equivalent common shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
UNITEDHEALTH GROUP INC executive Timothy John Noel, Chief Executive Officer of UnitedHealthcare, received an acquisition of 102.329 shares of common stock as of March 17, 2026. These shares represent dividend equivalents on outstanding restricted stock units and are granted at no cash cost to him.
After this award, his directly held common stock position reported in this filing increased to 17,574.653 shares. The dividend equivalents are subject to the same vesting conditions as the underlying restricted stock units and will be forfeited if those units do not vest, making this a routine, compensation-related equity accrual rather than an open‑market purchase.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Noel Timothy John
Role
Chief Executive Officer, UHC
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 102.329 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 17,574.653 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did UNH executive Timothy John Noel report?
Timothy John Noel reported receiving 102.329 UnitedHealth Group common shares as a dividend-equivalent award. These shares relate to his restricted stock units and involve no cash payment, reflecting routine equity-based compensation rather than an open-market purchase or sale.
Did Timothy John Noel buy or sell UNH stock on the open market?
The filing shows no open-market purchases or sales by Timothy John Noel. Instead, he acquired 102.329 shares through a grant classified as a dividend-equivalent award tied to restricted stock units, with a reported per-share price of zero dollars.
Does this UNH Form 4 indicate any derivative or option exercises?
This Form 4 does not report any derivative or option exercises for UnitedHealth Group securities. The only transaction is a non-derivative acquisition of common stock through dividend-equivalent shares associated with previously granted restricted stock units.